Extended Data Fig. 6: Landmark analysis at 8 weeks representing ctDNA-based MRD testing to be Predictive of Response to ACT in Post-Surgical CRC Patients.
From: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Kaplan-Meier estimates for disease-free survival stratified by observation (red) and adjuvant chemotherapy (blue) in pathological high-risk stage II/Stage III CRC patients with A. ctDNA positivity at 4-weeks after surgery; HR was adjusted by sex, and performance status. B. ctDNA negativity at 4-weeks after surgery; HR was adjusted by age, p-stage, MSI and performance status. A landmark analysis at 8 weeks was implemented to address the immortal time bias, whereby DFS was measured starting from day 60. Hazard ratio (HR) and 95% CI were calculated by the Cox proportional hazard model. P-value was calculated using the two-sided log-rank test.
